Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 should be refrigerated. The KB Solution is more effective at delivering RU58841 to the scalp.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

The conversation discusses using non-denatured ethanol for RU58841. Treatments mentioned include Minoxidil, finasteride, and RU58841.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

People are discussing ketoconazole shampoos that don't dry out hair, with suggestions including using it as a topical treatment, switching to T-Sal, and using moisturizing products like hyaluronic acid serum and biotin conditioner. Regenepure DR is confirmed to still contain ketoconazole, and some users recommend using moisturizing shampoos and conditioners to prevent dryness.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.

The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.

Serevelle is being considered for hair loss due to menopause, but its effectiveness is unclear. Minoxidil and hormone management are suggested alternatives.

The conversation discusses using topical serenoa oil, a natural anti-DHT treatment, for hair loss. It is considered less effective than finasteride and dutasteride but can be added to a routine with topical minoxidil.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

Minoxidil, alfatradiol, nizoral, and pyrilutamide can maintain hair for those who can't tolerate finasteride. Consistent use of these treatments can help prevent further hair loss.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.